References

1. Elghetany MT, Hudnall SD, Gardner FH: Peripheral blood picture in primary hypocellular refractory anemia and idiopathic acquired aplastic anemia: an additional tool for differential diagnosis. Haematologica 82:21-24, 1997.

2. Barrett J, Saunthararajah Y, Molldrem J: Myelodysplastic syndrome and aplastic anemia: distinct entities or diseases linked by a common pathophysiology? Semin Hematol 37:15-29, 2000.

3. Tuzuner N, Cox C, Rowe JM, Watrous D, Bennett JM: Hypocellular myelodysplastic syndromes (MDS): new proposals. Br J Haematol 91:612-617, 1995.

4. Szklo M, Sensenbrenner L, Markowitz J, et al.: Incidence of aplastic anemia in metropolitan Baltimore: a population-based study. Blood 66:115-119, 1985.

5. Mary JY, Baumelou E, Guiguet M: Epidemiology of aplastic anemia in France: a prospective multicentric study. The French Cooperative Group for epidemiologi-cal study of aplastic anemia. Blood 75:1646-1653, 1990.

6. Kaufman D, Kelly JP, Levy M, Shapiro S: The drug etiology of agranulocytosis and aplastic anemia. New York: Oxford University Press; 1991.

7. Issaragrisil S, Kaufman D, Thongput A, et al.: Association of seropositivity for hepatitis viruses and aplastic anemia in Thailand. Hepatology 25:1255-1257, 1997.

8. Young N, Maciejewski JP: Aplastic anemia. In: Hoffman R, Benz EJJ, Shattil SJ, et al. (eds.) Hematology: Basic Principles and Practice. Philadelphia: Churchill Livingstone; 2000:297-330.

9. Young NS: Acquired aplastic anemia. Ann Intern Med 136:534-546, 2002.

10. Arseniev L, Tischler HJ, Battmer K, et al.: Treatment of poor marrow graft function with allogeneic CD34+ cells immunoselected from G-CSF-mobilized peripheral blood progenitor cells of the marrow donor. Bone Marrow Transplant 14:791-797, 2002.

11. Baverstock KF, Ash PJ: A review of radiation accidents involving whole body exposure and the relevance to the LD50/60 for man. Br J Radiol 56:837-844, 1983.

12. Castro-Malaspina H, Harris RE, Gajewski J, et al.: Unrelated donor marrow transplantation for myelodys-plastic syndromes: outcome analysis in 510 transplants facilitated by the National Marrow Donor Program. Blood 99:1943-1951, 2002.

13. Novitzky N, Jacobs P: In aplastic anemia progenitor cells have a reduced sensitivity to the effects of growth factors. Eur J Haematol 63:141-148, 1999.

14. Bacigalupo A, Piaggio G, Podesta M, et al.: Collection of peripheral blood hematopoietic progenitors (PBHP)

evolve in up to 10% of AA patients over the period of 10 years. Currently, there are no good predictive factors, and most of the current data are derived from an older cohort of patients. It remains unclear whether AA patients who developed PNH did have minor PNH clones detectable at presentation, or whether their PNH developed truly de novo. PNH can be a disabling chronic complication of AA and is associated with hemolysis, transfusion dependence, and thrombotic complications.

from patients with severe aplastic anemia (SAA) after prolonged administration of granulocyte colony-stimulating factor. Blood 82:1410-1414, 1993.

15. Manz CY, Nissen C, Wodnar-Filipowicz A: Deficiency of CD34+ c-kit+ and CD34+38- hematopoietic precursors in aplastic anemia after immunosuppressive treatment. Am J Hematol 52:264-274, 1996.

16. Scopes J, Bagnara M, Gordon-Smith EC, Ball SE, Gibson FM: Haemopoietic progenitor cells are reduced in aplastic anaemia. Br J Haematol 86:427-430, 1994.

17. Marsh JC: Hematopoietic growth factors in the patho-genesis and for the treatment of aplastic anemia. Semin Hematol 37:81-90, 2000.

18. Wodnar-Filipowicz A, Yancik S, Moser Y, et al.: Levels of soluble stem cell factor in serum of patients with aplastic anemia. Blood 81:3259-3264, 1993.

19. Marsh JC, Gibson FM, Prue RL, et al.: Serum throm-bopoietin levels in patients with aplastic anaemia. Br J Haematol 95:605-610, 1996.

20. Chang KL, O'Donnell MR, Slovak ML, et al.: Primary myelodysplasia occurring in adults under 50 years old: a clinicopathologic study of 52 patients. Leukemia 16:623-631, 2002.

21. Podesta M, Piaggio G, Frassoni F, et al.: The assessment of the hematopoietic reservoir after immunosuppres-sive therapy or bone marrow transplantation in severe aplastic anemia. Blood 91:1959-1965, 1998.

22. Marsh JC, Chang J, Testa NG, Hows JM, Dexter TM: In vitro assessment of marrow "stem cell" and stromal cell function in aplastic anaemia. Br J Haematol 78:258-267, 1991.

23. Novitzky N, Jacobs P: Immunosuppressive therapy in bone marrow aplasia: the stroma functions normally to support hematopoiesis. Exp Hematol 23:1472-1477, 1995.

24. Novitzky N, Jacobs P: Marrow stem cell and stroma cell function in aplastic anaemia. Br J Haematol 79:531-533, 1991.

25. Laver J, Jhanwar SC, O'Reilly RJ, Castro-Malaspina H: Host origin of the human hematopoietic microenvironment following allogeneic bone marrow transplantation. Blood 70:1966-1968, 1987.

26. Rizzo S, Scopes J, Elebute MO, et al.: Stem cell defect in aplastic anemia: reduced long term culture-initiating cells (LTC-IC) in CD34+ cells isolated from aplastic anemia patient bone marrow. Hematol J 3:230-236, 2002.

27. Selleri C, Sato T, Anderson S, Young NS, Maciejewski JP: Interferon-gamma and tumor necrosis factor-alpha suppress both early and late stages of hematopoiesis and induce programmed cell death. J Cell Physiol 165:538-546, 1995.

28. Selleri C, Maciejewski JP, Sato T, Young NS: Interferon-gamma constitutively expressed in the stromal microenvironment of human marrow cultures mediates potent hematopoietic inhibition . Blood 87:4149-4157, 1996.

29. Kojima S, Matsuyama T, Kato S, et al.: Outcome of 154 patients with severe aplastic anemia who received transplants from unrelated donors: the Japan Marrow Donor Program. Blood 100:799-803, 2002.

30. Killick SB, Cox CV, Marsh JC, Gordon-Smith EC, Gibson FM: Mechanisms of bone marrow progenitor cell apoptosis in aplastic anaemia and the effect of anti-thymocyte globulin: examination of the role of the Fas-Fas-L interaction. Br J Haematol 111:1164-1169, 2000.

31. Ismail M, Gibson FM, Gordon-Smith EC, Rutherford TR: Bcl-2 and Bcl-x expression in the CD34+ cells of aplastic anaemia patients: relationship with increased apoptosis and upregulation of Fas antigen. Br J Haematol 113:706-712, 2001.

32. Maciejewski JP, Selleri C, Sato T, et al.: Nitric oxide suppression of human hematopoiesis in vitro. Contribution to inhibitory action of interferon-gamma and tumor necrosis factor-alpha. J Clin Invest 96:1085-1092, 1995.

33. Chung IJ, Lee JJ, Nam CE, et al.: Increased inducible nitric oxide synthase expression and nitric oxide concentration in patients with aplastic anemia. Ann Hematol 82:104-108, 2003.

34. Maciejewski JP, Risitano A, Sloand EM, Nunez O, Young NS: Distinct clinical outcomes for cytogenetic abnormalities evolving from aplastic anemia. Blood 99:3129-3135, 2002.

35. Maciejewski JP, Selleri C: Evolution of clonal cytoge-netic abnormalities in aplastic anemia. Leuk Lymphoma 45:433-440, 2004.

36. Brummendorf TH, Dragowska W, Lansdorp PM: Asymmetric cell divisions in hematopoietic stem cells. Ann N Y Acad Sci 872:265-272, 1999.

37. Brummendorf TH, Rufer N, Holyoake TL, et al.: Telomere length dynamics in normal individuals and in patients with hematopoietic stem cell-associated disorders. Ann N Y Acad Sci 938:293-303, 2001.

38. Brummendorf TH, Maciejewski JP, Mak J, Young NS, Lansdorp PM: Telomere length in leukocyte subpopulations of patients with aplastic anemia. Blood 97:895-900, 2001.

39. Ball SE, Gibson FM, Rizzo S, et al.: Progressive telomere shortening in aplastic anemia. Blood 91:3582-3592, 1998.

40. Lee JJ, Kook H, Chung IJ, et al.: Telomere length changes in patients with aplastic anaemia. Br J Haematol 112:1025-1030, 2001.

41. Young N: Drugs and chemicals. Young NS, Alter BP (eds.) Aplastic Anemia, Acquired and Inherited. Philadelphia: WB Sunders; 1994:100.

42. Smith MT: Overview of benzene-induced aplastic anaemia. Eur J Haematol Suppl 60:107-110, 1996.

43. Ross D: Metabolic basis of benzene toxicity. Eur J Haematol Suppl 60:111-118, 1996.

44. Aksoy M, Dincol K, Akgun T, Erdem S, Dincol G: Haematological effects of chronic benzene poisoning in 217 workers. Br J Ind Med 28:296-302, 1971.

45. Smick KM, Condit PK, Proctor RL, Sutcher V: Fatal aplastic anemia. An epidemiological study of its relationship to the drug chloramphenicol. J Chronic Dis 17:899-914, 1964.

46. Keiser G, Bolli P, Buchegger U: Hematologic side effects of chloramphenicol and thiamphenicol. Schweiz Med Wochenschr 102:1595-1598, 1972.

47. Mole RH: The LD50 for uniform low LET irradiation of man. Br J Radiol 57:355-369, 1984.

48. Torok-Storb B, Bolles L, Iwata M, et al.: Increased prevalence of CMV gB3 in marrow of patients with aplastic anemia. Blood 98:891-892, 2001.

49. Fries BC, Khaira D, Pepe MS, Torok-Storb B: Declining lymphocyte counts following cytomegalovirus (CMV) infection are associated with fatal CMV disease in bone marrow transplant patients. Exp Hematol 21:1387-1392, 1993.

50. Fries BC, Chou S, Boeckh M, Torok-Storb B: Frequency distribution of cytomegalovirus envelope glycoprotein genotypes in bone marrow transplant recipients. J Infect Dis 169:769-774, 1994.

51. Baranski B, Armstrong G, Truman JT, et al.: Epstein-Barr virus in the bone marrow of patients with aplastic anemia. Ann Intern Med 109:695-704, 1988.

52. Brown KE, Tisdale J, Barrett AJ, Dunbar CE, Young NS: Hepatitis-associated aplastic anemia. N Engl J Med 336:1059-1064, 1997.

53. Hoffman R, Zanjani ED, Lutton JD, Zalusky R, Wasserman LR: Suppression of erythroid-colony formation by lymphocytes from patients with aplastic anemia. N Engl J Med 296:10-13, 1977.

54. Takaku F, Suda T, Mizoguchi H, et al.: Effect of peripheral blood mononuclear cells from aplastic anemia patients on the granulocyte-macrophage and erythroid colony formation in samples from normal human bone marrow in vitro—a cooperative work. Blood 55:937-943, 1980.

55. Barcena A, Muench MO, Song KS, Ohkubo T, Harrison MR: Role of CD95/Fas and its ligand in the regulation of the growth of human CD34(++)CD38(-) fetal liver cells. Exp Hematol 27:1428-1439, 1999.

56. Horikawa K, Nakakuma H, Kawaguchi T, et al.: Apoptosis resistance of blood cells from patients with paroxysmal nocturnal hemoglobinuria, aplastic anemia, and myelodysplastic syndrome. Blood 90:2716-2722, 1997.

57. Abe M, Shintani Y, Eto Y, et al.: Potent induction of activin A secretion from monocytes and bone marrow stromal fibroblasts by cognate interaction with activated T cells. JLeukoc Biol 72:347-352, 2002.

58. Zeng W, Nakao S, Takamatsu H, et al.: Characterization of T-cell repertoire of the bone marrow in immunemediated aplastic anemia: evidence for the involvement of antigen-driven T-cell response in cyclosporine-dependent aplastic anemia. Blood 93:3008-3016, 1999.

59. Karadimitris A, Manavalan JS, Thaler HT, et al.: Abnormal T-cell repertoire is consistent with immune process underlying the pathogenesis of paroxysmal nocturnal hemoglobinuria. Blood 96:2613-2620, 2000.

60. Zeng W, Maciejewski JP, Chen G, Young NS: Limited heterogeneity of T cell receptor BV usage in aplastic anemia. J Clin Invest 108:765-773, 2001.

61. Kook H, Risitano AM, Zeng W, et al.: Changes in T-cell receptor VB repertoire in aplastic anemia: effects of different immunosuppressive regimens. Blood 99: 3668-3675, 2002.

62. Mauritzson N, Albin M, Rylander L, et al.: Pooled analysis of clinical and cytogenetic features in treatment-related and de novo adult acute myeloid leukemia and myelodysplastic syndromes based on a consecutive series of 761 patients analyzed 1976-1993 and on 5098 unselected cases reported in the literature 1974-2001. Leukemia 16:2366-2378, 2002.

63. Plasilova M: Paroxysmal nocturnal hemoglobinuria—in the search for disease-specific T-cell clones. Blood 100: 167A, 2002.

64. Risitano A, Maciejewski JP: TCR sequencing. The molecular signature of autoimmunity in aplastic anemia. Blood 100:155A, 2002.

65. Plasilova M, Risitano A, Maciejewski JP: Application of the molecular analysis of the T cell receptor repertoire in the study of immune-mediated hematologic disease. Hematol J 8:173-181, 2003.

66. Campisi J: Cellular senescence as a tumor-suppressor mechanism. Trends Cell Biol 11:S27-S31, 2001.

67. Sloand E, Maciejewski JP, Tisdale J, Follman D, Young NS: Intracellular interferon-y (IFN-y) in circulating and marrow T Cells detected by flow cytometry and the response to immunosuppressive therapy in patients with aplastic anemia. Blood 100:3129-3135, 2002.

68. Dufour C, Corcione A, Svahn J, et al.: Interferon gamma and tumour necrosis factor alpha are overex-pressed in bone marrow T lymphocytes from paediatric patients with aplastic anaemia. Br J Haematol 115: 1023-1031, 2001.

69. Camitta BM, Rappeport JM, Parkman R, Nathan DG: Selection of patients for bone marrow transplantation in severe aplastic anemia. Blood 45:355-363, 1975.

70. Maciejewski JP, Rivera C, Kook H, Dunn D, Young NS: Relationship between bone marrow failure syndromes and the presence of glycophosphatidyl inositol-anchored protein-deficient clones. Br J Haematol 115:1015-1022, 2001.

71. Dunn DE, Tanawattanacharoen P, Boccuni P, et al.: Paroxysmal nocturnal hemoglobinuria cells in patients with bone marrow failure syndromes. Ann Intern Med 131:401-408, 1999.

72. Young NS: The problem of clonality in aplastic anemia: Dr Dameshek's riddle, restated. Blood 79:1385-1392, 1992.

73. Alvarez S, MacGrogan D, Calasanz MJ, Nimer SD, Jhanwar SC: Frequent gain of chromosome 19 in megakaryoblastic leukemias detected by comparative genomic hybridization. Genes Chromosomes Cancer 32:285-293, 2001.

74. Hibbs JR, Frickhofen N, Rosenfeld SJ, et al.: Aplastic anemia and viral hepatitis. Non-A, Non-B, Non-C? JAMA 267:2051-2054, 1992.

75. Tichelli A, Socie G, Marsh J, et al.: Outcome of pregnancy and disease course among women with aplastic anemia treated with immunosuppression. Ann Intern Med 137:164-172, 2002.

76. Choudhry VP, Gupta S, Gupta M, Kashyap R, Saxena R: Pregnancy associated aplastic anemia—a series of 10 cases with review of literature. Hematology 7:233-238, 2002.

77. Di Bona E, Rodeghiero F, Bruno B, et al.: Rabbit antithy-mocyte globulin (r-ATG) plus cyclosporine and granulo-cyte colony stimulating factor is an effective treatment for aplastic anaemia patients unresponsive to a first course of intensive immunosuppressive therapy.

Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Br J Haematol 107:330-334, 1999.

78. Frickhofen N, Heimpel H, Kaltwasser JP, Schrezenmeier H: Antithymocyte globulin with or without cyclosporin A: 11-year follow-up of a randomized trial comparing treatments of aplastic anemia. Blood 101:1236-1242, 2003.

79. Nakao S, Takami A, Takamatsu H, et al.: Isolation of a T-cell clone showing HLA-DRB1*0405-restricted cytotoxicity for hematopoietic cells in a patient with aplastic anemia. Blood 89:3691-3699, 1997.

80. Murphy KM, Levis M, Hafez MJ, et al.: Detection of FLT3 internal tandem duplication and D835 mutations by a multiplex polymerase chain reaction and capillary electrophoresis assay. J Mol Diagn 5:96-102, 2003.

81. Rosenfeld S, Follmann D, Nunez O, Young NS: Antithymocyte globulin and cyclosporine for severe aplastic anemia: association between hematologic response and long-term outcome. JAMA 289:1130-1135, 2003.

82. Marsh J, Schrezenmeier H, Marin P, et al.: Prospective randomized multicenter study comparing cyclosporin alone versus the combination of antithymocyte globulin and cyclosporin for treatment of patients with nonsevere aplastic anemia: a report from the European Blood and Marrow Transplant (EBMT) Severe Aplastic Anaemia Working Party. Blood 93:2191-2195, 1999.

83. Gluckman E, Esperou-Bourdeau H, Baruchel A, et al.: Multicenter randomized study comparing cyclosporine-A alone and antithymocyte globulin with prednisone for treatment of severe aplastic anemia. Blood 79:2540-2546, 1992.

84. Coakley G, Brooks D, Iqbal M, et al.: Major histocom-patility complex haplotypic associations in Felty's syndrome and large granular lymphocyte syndrome are secondary to allelic association with HLA-DRB1 *0401. Rheumatology (Oxford) 39:393-398, 2000.

85. Frickhofen N, Kaltwasser JP: Immunosuppressive treatment of aplastic anemia: a prospective, randomized multicenter trial evaluating antilymphocyte globulin (ALG) versus ALG and cyclosporin A. Blut 56:191-192, 1988.

86. Tichelli A, Socie G, Henry-Amar M, et al.: Effectiveness of immunosuppressive therapy in older patients with aplastic anemia. European Group for Blood and Marrow Transplantation Severe Aplastic Anaemia Working Party. Ann Intern Med 130:193-201, 1999.

87. Gluckman E, Rokicka-Milewska R, Hann I, et al.: Results and follow-up of a phase III randomized study of recombinant human-granulocyte stimulating factor as support for immunosuppressive therapy in patients with severe aplastic anaemia. Br J Haematol 119: 1075-1082, 2002.

88. Maciejewski JP, Follmann D, Nakamura R, et al.: Increased frequency of HLA-DR2 in patients with paroxysmal nocturnal hemoglobinuria and the PNH/aplastic anemia syndrome. Blood 98:3513-3519, 2001.

89. Brodsky RA, Sensenbrenner LL, Smith BD, et al.: Durable treatment-free remission after high-dose cyclophos-phamide therapy for previously untreated severe aplastic anemia. Ann Intern Med 135:477-483, 2001.

90. Tisdale JF, Dunn DE, Geller N, et al.: High-dose cyclophosphamide in severe aplastic anaemia: a randomised trial. Lancet 356:1554-1559, 2000.

91. Tisdale JF, Maciejewski JP, Nunez O, Rosenfeld SJ, Young NS: Late complications following treatment for severe aplastic anemia (SAA) with high-dose cyclophosphamide (Cy): follow-up of a randomized trial. Blood 100:4668-4670, 2002.

92. Tisdale JF, Dunn DE, Maciejewski J: Cyclophosphamide and other new agents for the treatment of severe aplas-tic anemia. Semin Hematol 37:102-109, 2000.

93. Locasciulli A, Bruno B, Rambaldi A, et al.: Treatment of severe aplastic anemia with antilymphocyte globulin, cyclosporine and two different granulocyte colony-stimulating factor regimens: a GITMO prospective randomized study. Haematologica 89:1054-1061, 2004.

94. Hirota Y: Effects of androstanes on aplastic anemia—a prospective study. Nippon Ketsueki Gakkai Zasshi 44:1341-1359, 1981.

95. Najean Y, Haguenauer O: Long-term (5 to 20 years) Evolution of nongrafted aplastic anemias. The Cooperative Group for the Study of Aplastic and Refractory Anemias. Blood 76:2222-2228, 1990.

96. Locatelli F, Bruno B, Zecca M, et al.: Cyclosporin A and short-term methotrexate versus cyclosporin A as graft versus host disease prophylaxis in patients with severe aplastic anemia given allogeneic bone marrow transplantation from an HLA-identical sibling: results of a GITMO/EBMT randomized trial. Blood 96:1690-1697, 2000.

97. Bacigalupo A, Oneto R, Bruno B, et al.: Current results of bone marrow transplantation in patients with acquired severe aplastic anemia. Report of the European Group for Blood and Marrow transplantation. On behalf of the Working Party on Severe Aplastic Anemia of the European Group for Blood and Marrow Transplantation. Acta Haematol 103:19-25, 2000.

98. Kojima S, Horibe K, Inaba J, et al.: Long-term outcome of acquired aplastic anaemia in children: comparison between immunosuppressive therapy and bone marrow transplantation. Br J Haematol 111:321-328, 2000.

99. Margolis D, Camitta B, Pietryga D, et al.: Unrelated donor bone marrow transplantation to treat severe aplastic anaemia in children and young adults. Br J Haematol 94:65-72, 1996.

100. Horowitz MM: Current status of allogeneic bone marrow transplantation in acquired aplastic anemia. Semin Hematol 37:30-42, 2000.

101. Margolis DA, Casper JT: Alternative-donor hematopoi-etic stem-cell transplantation for severe aplastic anemia. Semin Hematol 37:43-55, 2000.

102. Georges GE, Storb R: Stem cell transplantation for aplastic anemia. Int J Hematol 75:141-146, 2002.

103. Kojima S, Inaba J, Yoshimi A, et al.: Unrelated donor marrow transplantation in children with severe aplas-tic anaemia using cyclophosphamide, anti-thymocyte globulin and total body irradiation. Br J Haematol 114:706-711, 2001.

104. Appelbaum FR, Barrall J, Storb R, et al.: Clonal cytoge-netic abnormalities in patients with otherwise typical aplastic anemia. Exp Hematol 15:1134-1139, 1987.

105. Varma N, Varma S, Movafagh A, Garewal G: Unusual clonal cytogenetic abnormalities in aplastic anemia. Am J Hematol 49:256-257, 1995.

106. Molldrem JJ, Leifer E, Bahceci E, et al.: Antithymocyte globulin for treatment of the bone marrow failure associated with myelodysplastic syndromes. Ann Intern Med 137:156-163, 2002.

107. Selleri C, Maciejewski JP, Catalano L, et al.: Effects of cyclosporine on hematopoietic and immune functions in patients with hypoplastic myelodysplasia: in vitro and in vivo studies. Cancer 95:1911-1922, 2002.

108. Kaito K, Kobayashi M, Katayama T, et al.: Long-term administration of G-CSF for aplastic anaemia is closely related to the early evolution of monosomy 7 MDS in adults. Br J Haematol 103:297-303, 1998.

109. Yamazaki E, Kanamori H, Taguchi J, et al.: The evidence of clonal evolution with monosomy 7 in aplastic anemia following granulocyte colony-stimulating factor using the polymerase chain reaction. Blood Cells Mol Dis 23:213-218, 1997.

110. Bessho M, Hotta T, Ohyashiki K, et al.: Multicenter prospective study of clonal complications in adult aplastic anemia patients following recombinant human granulocyte colony-stimulating factor (lenograstim) administration. Int J Hematol 77:152-158, 2003.

111. Kojima S, Hibi S, Kosaka Y, et al.: Immunosuppressive therapy using antithymocyte globulin, cyclosporine, and danazol with or without human granulocyte colony-stimulating factor in children with acquired aplastic anemia. Blood 96:2049-2054, 2000.

112. Bacigalupo A, Brand R, Oneto R, et al.: Treatment of acquired severe aplastic anemia: bone marrow transplantation compared with immunosuppressive therapy—the European Group for Blood and Marrow Transplantation experience. Semin Hematol 37:69-80, 2000.

113. Paquette RL, Tebyani N, Frane M, et al.: Long-term outcome of aplastic anemia in adults treated with antithy-mocyte globulin: comparison with bone marrow transplantation. Blood 85:283-290, 1995.

114. de Planque MM, Kluin-Nelemans HC, van Krieken HJ, et al.: Evolution of acquired severe aplastic anaemia to myelodysplasia and subsequent leukaemia in adults. Br J Haematol 70:55-62, 1988.

115. Jameel T, Anwar M, Abdi SI, et al.: Aplastic anemia or aplastic preleukemic syndrome? Ann Hematol 75:189-193, 1997.

116. Young NS, Maciejewski JP: Aplastic anemia. In: Hoffman R (ed.) Hematology: Basic Priciples and Practice. Philadelphia: Churchill Livingstone; 1995:297-331.

117. Doney K, Leisenring W, Storb R, Appelbaum FR: Primary treatment of acquired aplastic anemia: outcomes with bone marrow transplantation and immunosuppressive therapy. Seattle Bone Marrow Transplant Team. Ann Intern Med 126:107-115, 1997.

118. Socie G, Henry-Amar M, Bacigalupo A, et al.: Malignant tumors occurring after treatment of aplastic anemia. European Bone Marrow Transplantation— Severe Aplastic Anaemia Working Party. N Engl J Med 329:1152-1157, 1993.

119. Socie G, Rosenfeld S, Frickhofen N, Gluckman E, Tichelli A: Late clonal diseases of treated aplastic anemia. Semin Hematol 37:91-101, 2000.

120. Anthony DD, Heeger PS, Haqqi TM: Immunization with TCR Vbeta10 peptide reduces the frequency of type-II collagen-specific Th1 type T cells in BUB/BnJ (H-2q) mice. Clin Exp Rheumatol 19:385-394, 2001.

121. Gaschet J, Lim A, Liem L, et al.: Acute graft versus host disease due to T lymphocytes recognizing a single

HLA-DPB1*0501 mismatch. J Clin Invest 98:100-107, 1996.

122. Ohga S, Ohara A, Hibi S, et al.: Treatment responses of childhood aplastic anaemia with chromosomal aberrations at diagnosis. Br J Haematol 118:313-319, 2002.

123. Geary CG, Harrison CJ, Philpott NJ, et al.: Abnormal cytogenetic clones in patients with aplastic anaemia: response to immunosuppressive therapy. Br J Haematol 104:271-274, 1999.

124. Mikhailova N, Sessarego M, Fugazza G, et al.: Cytogenetic abnormalities in patients with severe aplastic anemia. Haematologica 81:418-422, 1996.

125. Bacigalupo A, Bruno B, Saracco P, et al.: Antilymphocyte globulin, cyclosporine, prednisolone, and granulocyte colony-stimulating factor for severe aplastic anemia: an update of the GITMO/EBMT study on 100 patients. European Group for Blood and Marrow Transplantation (EBMT) Working Party on Severe Aplastic Anemia and the Gruppo Italiano Trapianti di Midolio Osseo (GITMO). Blood 95:1931-1934, 2000.

126. Frickhofen N, Heimpel H, Kaltwasser JP, Schrezenmeier H: Antithymocyte globulin with or without cyclosporin A: 11-year follow-up of a randomized trial comparing treatments of aplastic anemia. Blood 101:1236-1242, 2003.

127. Fuhrer M, Burdach S, Ebell W, et al.: Relapse and clonal disease in children with aplastic anemia (AA) after immunosuppressive therapy (IST): the SAA 94 experience. German/Austrian Pediatric Aplastic Anemia Working Group. Klin Padiatr 210:173-179, 1998.

128. Ohara A, Kojima S, Okamura J, et al.: Evolution of myelodysplastic syndrome and acute myelogenous leukaemia in children with hepatitis-associated aplastic anaemia. Br J Haematol 116:151-154, 2002.

129. Ishiyama K, Karasawa M, Miyawaki S, et al.: Aplastic anaemia with 13q-: a benign subset of bone marrow failure responsive to immunosuppressive therapy. Br J Haematol 117:747-750, 2002.

130. Kojima S, Ohara A, Tsuchida M, et al.: Risk factors for evolution of acquired aplastic anemia into myelodys-plastic syndrome and acute myeloid leukemia after immunosuppressive therapy in children. Blood 100:786-790, 2002.

131. Michalova K, Musilova J, Zemanova Z: Cytogenetic abnormalities in 532 patients with myeloid leukemias and myelodysplastic syndrome. The Czechoslovak MDS Cooperative Group. Czech Med 13:133-144, 1990.

132. Sole F, Espinet B, Sanz GF, et al.: Incidence, characterization and prognostic significance of chromosomal abnormalities in 640 patients with primary myelodysplastic syndromes. Grupo Cooperativo Espanol de Citogenetica Hematologica. Br J Haematol 108:346-356, 2000.

133. Vila L, Charrin C, Archimbaud E, et al.: Correlations between cytogenetics and morphology in myelodys-plastic syndromes. Blut 60:223-227, 1990.

134. Bernasconi P, Alessandrino EP, Boni M, et al.: Karyotype in myelodysplastic syndromes: relations to morphology, clinical evolution, and survival. Am J Hematol 46:270-277, 1994.

135. Knapp RH, Dewald GW, Pierre RV: Cytogenetic studies in 174 consecutive patients with preleukemic or myelodysplastic syndromes. Mayo Clin Proc 60: 507-516, 1985.

136. Suciu S, Kuse R, Weh HJ, Hossfeld DK: Results of chromosome studies and their relation to morphology, course, and prognosis in 120 patients with de novo myelodysplastic syndrome. Cancer Genet Cytogenet 44: 15-26, 1990.

137. Pedersen B: MDS and AML with trisomy 8 as the sole chromosome aberration show different sex ratios and prognostic profiles: a study of 115 published cases. Am J Hematol 56:224-229, 1997.

138. Kennedy B, Rawstron A, Carter C, et al.: Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia. Blood 99: 2245-2247, 2002.

139. Chen R, Nagarajan S, Prince GM, et al.: Impaired growth and elevated fas receptor expression in PIGA(+) stem cells in primary paroxysmal nocturnal hemoglo-binuria. J Clin Invest 106:689-696, 2000.

140. Brodsky RA, Vala MS, Barber JP, Medof ME, Jones RJ: Resistance to apoptosis caused by PIG-A gene mutations in paroxysmal nocturnal hemoglobinuria. Proc Natl Acad Sci USA 94:8756-8760, 199 7.

141. Yamamoto T, Shichishima T, Shikama Y, et al.: Granulocytes from patients with paroxysmal nocturnal hemoglobinuria and normal individuals have the same sensitivity to spontaneous apoptosis. Exp Hematol 30:187-194, 2002.

142. Ware RE, Nishimura J, Moody MA, et al.: The PIG-A mutation and absence of glycosylphosphatidylinositol-linked proteins do not confer resistance to apoptosis in paroxysmal nocturnal hemoglobinuria. Blood 92:2541-2550, 1998.

This page intentionally left blank

10 Ways To Fight Off Cancer

10 Ways To Fight Off Cancer

Learning About 10 Ways Fight Off Cancer Can Have Amazing Benefits For Your Life The Best Tips On How To Keep This Killer At Bay Discovering that you or a loved one has cancer can be utterly terrifying. All the same, once you comprehend the causes of cancer and learn how to reverse those causes, you or your loved one may have more than a fighting chance of beating out cancer.

Get My Free Ebook


Post a comment